Neurology

Neuroinflammation Pipeline Enables Patient Selection and PD

THE NEED

  • Chronic neuroinflammation correlates with poor outcomes in a wide range of diseases (e.g. ALS, Alzheimer’s, Parkinson’s)
  • Neuroinflammation is difficult to diagnose, and current agents lack sufficient selectivity

OUR SOLUTION

  • Radiolabeled (18F) HD, selectively images neuroinflammation in multiple animal models
  • Enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia
  • Observed to cross BBB in 7 species (young and aged)

STATUS:

Risk share via partnership for OP-801 while still maintaining companion diagnostic rights in neurology and cancer applications

Leveraging OP-801 to Achieve Human POC

OP-801: Powerful Proof of Concept for Selective Targeting

Imaged 60 minutes after OP-801 dose